The plasma concentration of VEGF, HE4 and CA125 as a new biomarkers panel in different stages and sub-types of epithelial ovarian tumors

Table 2 Plasma levels of VEGF, HE4 and CA125 in tested groups

Groups			VEGF	HE4	CA125
			(pg/ml)	(pmol/L)	(U/ml)
Ovarian cancer Median Range	stage I		^1/2	^1/2	¹
	stage I		166.18	83.50	63.50
			15.38 -656.56	28.60-1093.80	12.00-557.20
	stage II		^1/2	^1/2	^1/2
	stage II		170.50	62.60	61.45
			8.92-2701.07	27.00-625.10	9.80-998.00
	stage III		^1/2/4	^1/2/4	^1/2/4
	stage III		345.50	117.90	766.60
			10.70-1429.50	48.70-1500.00	10.10-2060.78
	stage IV		^1/2/4/5	^1/2/4	^1/2/4
	stage IV		143.50	198.00	531.90
			9.00-1386.00	37.80-1944.20	14.30-8602.30
	Total group		^1/2	^1/2	^1/2
	Total group		168.48	103.60	133.30
			8.92-2701.07	27.00-1944.20	9.80-8602.30
	*Serous epithelial*		^1/6	^1/6/7/9	^1/6/7
	*Serous epithelial*		166.18	126.00	171.21
			8.92-1429.50	28.60-1944.20	9.80-8602.30
	*Endometrioid epithelial*		^1/6	^1/6/7	^1/6/7
	*Endometrioid epithelial*		184.24	68.45	114.00
			9.00-2701.07	27.00-1740.00	11.10-1425.00
Control groups Median Range	Benign ovarian tumor *(Cystis)*	*Endometrioides*			^3/8
		*Endometrioides*	45.50	23.15	43.75
			9.00-560.50	14.00-65.60	7.50-2748.00
		*Serous*	³	⁸	³
		*Serous*	84.35	43.25	20.65
			9.00-2100.00	26.80-156.40	5.80-451.80
		Total group			³
		Total group	68.71	42.50	27.70
			9.00-2100.00	14.00-156.40	5.80-2748.00
	Healthy subjects		39.31	44.15	9.94
			2.30-467.10	6.20-122.30	5.06-36.60

¹statistically significant when comparing OC patients with healthy subject.
²statistically significant when comparing OC patients with benign ovarian tumor total group.
³statistically significant when comparing patients with benign ovarian tumor and healthy subject.
⁴ statistically significant when comparing OC patients in stage III or IV with stage I or stage II.
⁵ statistically significant when comparing OC patients in stage IV with stage III.
⁶ statistically significant when comparing with benign ovarian tumor group. i.e. type cystis endometrioides.
⁷statistically significant when comparing with benign ovarian tumor group. i.e. type cystis serous.
⁸ statistically significant when comparing patients with benign ovarian tumor. i.e. type cystis endometrioides with type cystis serous.
⁹ statistically significant when comparing OC patients. i.e. sub-type serous epithelial with sub-type endometrioid epithelial.

ISSN: 1757-2215